Chemours Co(CC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,100 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
CC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Chemours Co (CC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CC at 36.5/100 on a 32-signal composite quality model, placing it at rank #2,100 of 2,879 stocks — the bottom half of the AI-ranked universe. CC scores in the top quartile across revenue scale (80.3). Areas of concern include profitability (21.8) and institutional flow (24.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Chemours Co reports quarterly revenue of $1.4B, net income of $-29.0M, an operating margin of -1.6%. Top institutional holders of CC by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CC trades on the NYSE exchange and files with the SEC under CIK 1627223. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Chemours Co directly from SEC EDGAR. Chemours Co's 13F Pro composite quality score has ranged between 8 and 71 since 2021, currently 36.5 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q1 2026
$1.4B
Net Income
Q1 2026
$-29.0M
Free Cash Flow
Q1 2026
$-93.0M
Operating Margin
Q1 2026
-1.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-4.9% YoYNet Income
+127.7% YoYEPS (Diluted)
+127.1% YoYTotal Assets
-9.0% YoYTotal Debt
+1.8% YoYOp. Cash Flow
-213.8% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $5.78B -4.9% | $6.08B -11.0% | $6.83B +7.7% | $6.34B +27.7% | $4.97B -10.1% | $5.53B |
| Net Income | $70.0M +127.7% | $-253.0M -143.8% | $578.0M -4.9% | $608.0M +177.6% | $219.0M +521.2% | $-52.0M |
| EPS (Diluted) | $0.46 +127.1% | $-1.70 -146.6% | $3.65 +1.4% | $3.60 +172.7% | $1.32 +512.5% | $-0.32 |
| Total Assets | $7.51B -9.0% | $8.25B +8.0% | $7.64B +1.2% | $7.55B +6.6% | $7.08B -2.4% | $7.26B |
| Total Debt | $4.11B +1.8% | $4.04B +11.2% | $3.63B -3.1% | $3.75B -6.9% | $4.03B -3.2% | $4.16B |
| Operating Cash Flow | $-633.0M -213.8% | $556.0M -26.4% | $755.0M -7.2% | $814.0M +0.9% | $807.0M +24.2% | $650.0M |
Get alerted when CC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Chemours Co including:
Top Institutional Holders of CC
BlackRock, Inc.
$493.2M22,385,850 shVANGUARD PORTFOLIO MANAGEMENT LLC
$227.5M10,325,341 shVANGUARD CAPITAL MANAGEMENT LLC
$149.2M6,773,917 shSTATE STREET CORP
$134.9M6,123,088 shAMERIPRISE FINANCIAL INC
$106.6M4,837,803 shAMERICAN CENTURY COMPANIES INC
$97.3M4,415,864 shWolf Hill Capital Management, LP
$81.3M3,689,794 shGEODE CAPITAL MANAGEMENT, LLC
$79.4M3,603,921 shGOLDMAN SACHS GROUP INC
$66.4M3,014,114 shD. E. Shaw & Co., Inc.
$62.8M2,851,010 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $493.2M | 22,385,850 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $227.5M | 10,325,341 |
| VANGUARD CAPITAL MANAGEMENT LLC | $149.2M | 6,773,917 |
| STATE STREET CORP | $134.9M | 6,123,088 |
| AMERIPRISE FINANCIAL INC | $106.6M | 4,837,803 |
| AMERICAN CENTURY COMPANIES INC | $97.3M | 4,415,864 |
| Wolf Hill Capital Management, LP | $81.3M | 3,689,794 |
| GEODE CAPITAL MANAGEMENT, LLC | $79.4M | 3,603,921 |
| GOLDMAN SACHS GROUP INC | $66.4M | 3,014,114 |
| D. E. Shaw & Co., Inc. | $62.8M | 2,851,010 |
More Healthcare Companies
View all Healthcare →Put CC on your watchlist
Track score changes the day Chemours Co files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CC a good stock to buy?
13F Pro's AI-powered analysis of Chemours Co (CC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CC are available on the CC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Chemours Co's investment landscape.